Skip to NavigationSkip to content

NICE recommends Harvoni for hepatitis C

Published on 03/03/15 at 07:55am
Harvoni image

NICE has signalled a provisional OK for Gilead’s Harvoni to be used as a treatment for hepatitis C by the NHS.

In draft guidance the healthcare watchdog approved Harvoni (ledipasvir-sofosbuvir) as a treatment for some people with genotype 1 or 4 chronic hepatitis C.

Already approved in the US and Europe to treat this patient type, Harvoni is taken orally as a fixed-dose combination tablet for 8, 12 or 24 weeks, with or without ribavirin.

NICE estimates a basic cost – without negotiated procurement discounts – for a 12-week course of Harvoni to be just under £40,000, and a 24-week course at just less than £80,000. In clinical trials the treatment achieved impressive cure weeks in people given an eight-week course.

On the other hand, NICE calculates Harvoni will achieve cost benefits of up to £77,500 for 24 weeks of treatment, compared with simeprevir plus peginterferon alfa and ribavirin per quality-adjusted life year (QALY) gained.

Gilead argues that the costs are ultimately offset if people with hepatitis C are prevented from developing complications due to viral progression like liver cirrhosis and liver cancer, and prevented from passing on the virus.

The NICE technology appraisal committee also considered Harvoni in combination with ribavirin for people with genotype 3 chronic hepatitis C – an indication that is included in the drug’s European marketing authorisation – but the committee concluded that “based on the evidence presented… that this could not be considered a cost-effective use of NHS resources”.

Commenting on the draft guidance Professor Carole Longson, director of the NICE centre for health technology evaluation, says the current mainstay of treatment for hepatitis C – interferon-based therapy – has side effects that may increase the likelihood that people aren’t treated.

“Ledipasvir- sofosbuvir offers the possibility of a shortened course of treatment without the need for combination therapy with interferon. This could make it more likely that people will seek treatment for their condition.

She adds: “In turn this could have important benefits, not just for people with chronic hepatitis, but also in reducing transmission of the virus to people without the infection. The Committee therefore acknowledged that ledipasvir-sofosbuvir is a valuable new therapy for treating chronic hepatitis C.”

Stelios Karagiannoglou who is the general manager for UK and Ireland at Gilead, says: “We are pleased that NICE has found this treatment to be a cost-effective use of NHS resources for some hepatitis C patients.

“Ledipasvir/sofosbuvir represents an opportunity to reduce overall NHS spending on hepatitis C because of improved treatment efficacy and tolerability, which allow more patients the potential to complete treatment and achieve cure.”

Lilian Anekwe

Draft recommendations in full:

  • Genotype 1 hep C virus: 8 weeks’ treatment recommended for treatment-naïve people without cirrhosis (12 weeks’ for those with cirrhosis), and 12 weeks’ for treatment-experienced people with no cirrhosis
  • Genotype 4 hep C virus: 12 weeks recommended for all people with cirrhosis.
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches